Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genentech

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

76 comunicati stampa

Guarda tutti i comunicati
09/03/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
Oncologia
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
06/03/2026
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
Fonte
Genentech
Emittente
Business Wire
1.00
0
05/03/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
Fonte
Genentech
Emittente
Business Wire
1.00
0
02/03/2026
Industria
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
Fonte
Genentech
Emittente
Business Wire
1.00
0
20/02/2026
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
Fonte
Genentech
Emittente
Business Wire
1.00
0
20/02/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
16/02/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease
Fonte
Genentech
Emittente
Business Wire
1.00
0
07/02/2026
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Industria
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
Fonte
Genentech
Emittente
Business Wire
1.00
0
27/01/2026
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
Fonte
Genentech
Emittente
Business Wire
1.00
0
20/01/2026
Biotecnologia
Industria
Salute
Farmaceutica
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility
Fonte
Genentech
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0